Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696
8/5/2014 6:04:47 AM
(Reuters) - Expectations are building for a new heart failure drug from Novartis viewed as a likely multibillion-dollar seller, with two surveys of cardiologists published on Tuesday highlighting its potential.
A large clinical trial with LCZ696 was stopped early in March because the benefit to patients was overwhelmingly positive. Just how good the drug was will be disclosed at a medical meeting in Spain at the end of this month.
The size of the benefit is critical in determining how widely LCZ696 might be used to treat millions of patients with chronic heart failure, in which the heart struggles to pump blood around the body efficiently.
Help employers find you! Check out all the jobs and post your resume.
comments powered by